1. Study identification
EU PAS Register NumberEUPAS10753
Official titleReal life assessment of chronic obstructive pulmonary disease Inhaler devices handling
Study title acronymINHALER
Study typeObservational study
Brief description of the studyThe correct use of inhalation devices is essential to ensure the effectiveness of the treatment (Giraud and Roche, Eur Respir J 2002). We have shown in a large study published in 2003 that many patients make handling errors in real life (Molimard et al., J Aerosol Med 2003, Girodet et al., Therapie 2003). Since this study, new devices have been marketed in chronic obstructive pulmonary disease (COPD), including Breezehaler® and Respimat®. Interestingly, little is known regarding their real-life use.
The aim of this study is to update data on device handling, including new devices, in a real-life setting in France.
The primary objective is to evaluate real-life COPD patient handling of their usual inhaler (Breezhaler®, Diskus®, Handihaler®, Respimat®, Turbuhaler® or pressurized Metered Dose Inhaler) by general practitioners or pulmonologists.
For this cross-sectional observational study, 1 000 GPs and 200 pulmonologists randomly selected from a geographically representative database, and who agree to participate in this study, will assess patient handling of their current inhaler. Five thousands patients will be requested to take a puff of their usual inhaler using their usual technique, which will be observed and rated by the physician. Patient characteristics, COPD history, and device use history, will be collected using a questionnaire.
For each device (if a patient has several devices, each device will be studied) descriptive statistical analysis will be performed: the handling error rate will be estimated overall (handling errors will be classified as those independent or dependent of the inhalation system, and among the latter major/critical errors will be identified), as well as stratified according to patient characteristics, COPD history, device use history, and patient-reported treatment effect. Sensitivity analyses will be performed excluding patients having been trained within 3 months.
Was this study requested by a regulator?No
Is the study required by a Risk Management Plan (RMP)?
Not applicable
Regulatory procedure number (RMP Category 1 and 2 studies only)
Other study registration identification numbers and URLs as applicable
2. Research centres and Investigator details
Coordinating study entity
Department/Research grouppharmacoepidemiology
Organisation/affiliationUniversity of Bordeaux
Details of (Primary) lead investigator
Title Professor
Last name MOLIMARD
First name Mathieu
Is this study being carried out with the collaboration of a research network?
No
Other centres where this study is being conducted
Not applicable (single centre)
Countries in which this study is being conducted
National study
France
3. Study timelines: initial administrative steps, progress reports and final report
PlannedActual
Date when funding contract was signed31/03/2014
Start date of data collection01/09/201424/03/2015
Start date of data analysis15/12/201512/01/2016
Date of interim report, if expected
Date of final study report30/09/201630/09/2016
4. Sources of funding
Please provide estimates of the percentage of funding by source for this study
Names(s)Approximate % funding
Pharmaceutical companiesNOVARTIS PHARMA S.A.S.85
Charities
Government body
Research councils
EU funding scheme
OtherPublic University: Université de Bordeaux15
5. Contact details for enquiries
Scientific Enquiries
Title Dr
Last name MOLIMARD
First name Mathieu
Address line 1Service de Pharmacologie - Université de Bordeaux - 146 Rue Leo Saignat
Address line 2
Address line 3
CityBordeaux
Postcode33076
CountryFrance
Phone number (incl. country code)33557571560
Alternative phone number
Fax number (incl. country code)33557574671
Public Enquiries
Title Dr
Last name MOLIMARD
First name Mathieu
Address line 1Service de Pharmacologie - Université de Bordeaux - 146 Rue Leo Saignat
Address line 2
Address line 3
CityBordeaux
Postcode33076
CountryFrance
Phone number (incl. country code)33557571560
Alternative phone number
Fax number (incl. country code)33557574671
6. Study drug(s) information
Not applicable (disease/epidemiology study)
7. Medical conditions to be studied
Medical condition(s)Yes
Chronic obstructive pulmonary disease
8. Population under study
Age
Adults (18 - 44 years)
Adults (45 - 64 years)
Adults (65 - 74 years)
Adults (75 years and over)
Sex
Male
Female
9. Number of subjects
Estimated total number of subjects5000
10. Source of data
Is this study being carried out with an established data source?No
Sources of data
Prospective patient-based data collection
11. Scope of the study
What is the scope of the study?
Disease epidemiology
Handling of medical devices
Primary scope : Handling of medical devices
12. Main objective(s)
What is the main objective of the study?
The objective is to assess COPD patient handling with their usual inhaler (Breezhaler®, Handihaler®, Diskus®, pMDI, Respimat® or Turbuhaler®) in real-life by general practitioners or pulmonologists.
Are there primary outcomes?No
Are there secondary outcomes?No
13. Study design
What is the design of the study?
Cross-sectional study
14. Follow-up of patients
Will patients be followed up?Not applicable/no follow-up
15. Data analysis plan
Please provide a brief summary of the analysis method
Statistical analysis will provide a description of the selection of physicians and patients in the study, the characteristics of physicians, the characteristics of patients included the handling of each COPD inhaler device, the handling error rate of the COPD inhaler devices, the characteristics of patients presenting a handling error for each type of error.
Statistical analysis will be performed after database lock using SAS® software.
The descriptive analysis of qualitative and ordinal variables will be presented using the frequency and the proportion of each modality. Quantitative variables will be presented using the size, number of patients with missing data, the arithmetic mean, standard deviation, the first quartile, median, third quartile, and extreme values.
Two-sided 95% confidence intervals (CI) will be assessed for the error rates. The CIs will be calculated using normal approximation, exact binomial or Poisson method according to the size of samples.